[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,179
  • Shares Outstanding, K 97,906
  • Annual Sales, $ 40,520 K
  • Annual Income, $ -160,060 K
  • EBIT $ -109 M
  • EBITDA $ -104 M
  • 60-Month Beta 2.16
  • Price/Sales 6.81
  • Price/Cash Flow N/A
  • Price/Book 62.63

Options Overview Details

View History
  • Implied Volatility 119.51% (-5.26%)
  • Historical Volatility 99.99%
  • IV Percentile 67%
  • IV Rank 17.48%
  • IV High 347.63% on 03/03/26
  • IV Low 71.18% on 01/16/26
  • Expected Move (DTE 14) 0.77 (25.87%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 404
  • Volume Avg (30-Day) 818
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 30,399
  • Open Int (30-Day) 26,375
  • Expected Range 2.22 to 3.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 5
  • High Estimate $-0.26
  • Low Estimate $-0.32
  • Prior Year $-0.63
  • Growth Rate Est. (year over year) +52.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +24.07%
on 05/26/26
3.94 -24.11%
on 05/27/26
-0.01 (-0.33%)
since 05/04/26
3-Month
1.82 +64.29%
on 03/06/26
3.94 -24.11%
on 05/27/26
+0.80 (+36.53%)
since 03/04/26
52-Week
1.66 +80.12%
on 02/05/26
4.54 -34.10%
on 10/08/25
+1.17 (+64.29%)
since 06/04/25

Most Recent Stories

More News
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced...

EDIT : 2.99 (+7.55%)
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the...

EDIT : 2.99 (+7.55%)
Editas Medicine Announces Proposed Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that...

EDIT : 2.99 (+7.55%)
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent...

EDIT : 2.99 (+7.55%)
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical...

EDIT : 2.99 (+7.55%)
Editas: Q1 Earnings Snapshot

Editas: Q1 Earnings Snapshot

EDIT : 2.99 (+7.55%)
Editas Medicine Announces First Quarter 2026 Results and Business Updates

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026  Company to present new EDIT-401 preclinical...

EDIT : 2.99 (+7.55%)
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.99 (+7.55%)
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector

With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....

CRSP : 56.95 (+9.35%)
EDIT : 2.99 (+7.55%)
NTLA : 14.75 (+13.29%)
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.99 (+7.55%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 3.20
2nd Resistance Point 3.05
1st Resistance Point 2.92
Last Price 2.99
1st Support Level 2.64
2nd Support Level 2.49
3rd Support Level 2.36

See More

52-Week High 4.54
Fibonacci 61.8% 3.44
Fibonacci 50% 3.10
Last Price 2.99
Fibonacci 38.2% 2.76
52-Week Low 1.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.